Tradestie Institutional Equity Comparison Engine · Market Close Nov 09, 2026

DAWN vs ACHV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DAWN Captures Overall Composite Edge (58.3 HOLD vs 56.6 HOLD), While ACHV Leads 3–2 on Growth & Valuation Pillars

DAWN Overall Winner 6-Pillar Tally: DAWN 2 – 3 ACHV (1 Tie) Matrix Metrics: DAWN 6 – 4 ACHV

As of Nov 09, 2026, Day One Biopharmaceuticals, Inc. (DAWN) captures the overall head-to-head institutional edge over Achieve Life Sciences, Inc. (ACHV) on higher Unified Composite conviction (58.3/100 HOLD vs. 56.6/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while ACHV wins 3–2 across the 6-pillar growth and valuation breakdown. DAWN trades at $21.53 (N/M Forward P/E, -51.1% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: DAWN earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. ACHV 56.6/100 HOLD) and 0.03β · 2% Vol risk profile, whereas ACHV leads top-line expansion (+0.0% YoY revenue growth, 17.68x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DAWN vs ACHV
DAWN NASDAQ Head-to-Head Winner
Day One Biopharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$21.53
+0.19% 1D
Market Cap $2.2B
TTM Revenue $158M
Forward P/E N/M
Beta / 30D Vol 0.03β · 2% Vol
Unified Composite Score
58.3 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 66.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (28.9% over 20 days), RSI 80
RSI-14: 80.5 · SMA20: $21.45 · SMA50: $18.01
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28

6-Pillar Scorecard Institutional Category Breakdown (DAWN 2 – 3 ACHV)

Columns: Metric · DAWN · ACHV
1. Valuation Multiples ACHV
Forward P/E N/M 35.3x
Trailing P/E N/M 35.3x
PEG Ratio N/M 17.68x
EV / Revenue 14.0x N/M
2. Growth & Scale DAWN
Revenue Growth (YoY) +83.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $158M N/A
Market Cap $2.2B $692.8M
3. Profitability & Quality ACHV
Gross Margin 89.1% N/A
Operating Margin -51.1% 0.0%
Net Profit Margin -67.8% 0.0%
Return on Equity (ROE) -22.7% -845.0%
4. Balance Sheet & Cash Flow ACHV
Cash Generation (TTM) -$124M EBITDA -$44M
Cash Flow Margin -78.6% EBITDA Mgn N/A
Net Cash / Leverage $4.28 Book/Sh · -22.7% ROE $46M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DAWN
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 0.6% (<1st %ile) 88.3% (23rd %ile)
Put/Call OI Skew 0.45x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DAWN (6) vs ACHV (4)
Institutional Metric DAWN ACHV Criterion Row Edge
Market Capitalization
Scale
$2.2B $692.8M Larger Scale DAWN
Trailing P/E Ratio
Valuation
N/M 35.3x Lower Multiple ACHV
Forward P/E Ratio
Valuation
N/M 35.3x Lower Multiple ACHV
Revenue Growth (YoY)
Growth
+83.9% +0.0% Higher Growth DAWN
Operating Margin (TTM)
Profitability
-51.1% 0.0% Higher Margin ACHV
Net Profit Margin
Profitability
-67.8% 0.0% Higher Margin ACHV
Return on Equity (ROE)
Capital Efficiency
-22.7% -845.0% Higher ROE DAWN
52-Week Range Position
Momentum
100% ($6–$22) 69% ($3–$9) Stronger Trend DAWN
Beta / 30D Volatility
Risk Regime
0.03β · 2% Vol 1.73β · 62% Vol Lower Realized Risk DAWN
Unified Institutional Score
Composite Signal
58.3 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite DAWN
Trailing 12M Revenue (USD)
Operating Scale
$158M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.0x EV/Rev 17.68x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$124M EBITDA ($4.28 Book/Sh · -22.7% ROE) -$44M ($46M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACHV +3.64 pp
DAWN: +0.8% · ACHV: +4.44%
3M Horizon DAWN +100.34 pp
DAWN: +78.38% · ACHV: -21.96%
6M Horizon DAWN +150.25 pp
DAWN: +139.49% · ACHV: -10.76%
1Y Horizon DAWN +150.25 pp
DAWN: +139.49% · ACHV: -10.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DAWN vs ACHV. Trailing 12-month operating profitability (DAWN -51.1% vs ACHV 0.0%) and valuation multiples (DAWN N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

DAWN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$158M
Gross Margin89.1%
Op. Margin-51.1%
ROE / Fwd P/E-22.7% · N/M
ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DAWN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.45x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact DAWN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DAWN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -51.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DAWN vs ACHV Key Questions & Quantitative Answers

As of Nov 09, 2026, Day One Biopharmaceuticals, Inc. (DAWN) captures the overall head-to-head institutional edge over Achieve Life Sciences, Inc. (ACHV) on higher Unified Composite conviction (58.3/100 HOLD vs. 56.6/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while ACHV wins 3–2 across the 6-pillar growth and valuation breakdown. DAWN trades at $21.53 (N/M Forward P/E, -51.1% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DAWN earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. ACHV 56.6/100 HOLD) and 0.03β · 2% Vol risk profile, whereas ACHV leads top-line expansion (+0.0% YoY revenue growth, 17.68x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

DAWN leads the Growth & Scale pillar: DAWN posts +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DAWN generates $158M in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, DAWN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.

ACHV screens cheaper on headline valuation multiples. DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DAWN (-22.7% ROE) versus ACHV (-845.0% ROE) capital efficiency.

In options market volatility and institutional positioning, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 09, 2026. For educational research only; not investment advice.